Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fujianfang Yisui is a Traditional Chinese Medicine (TCM) herbal formula developed by The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine for the treatment of ischemic stroke. Based on the "Yisui" (marrow-nourishing) therapeutic principle, the formula is specifically indicated for patients in the convalescent phase of stroke who exhibit marrow deficiency syndrome. It is designed to facilitate the recovery of motor function, reduce spasticity, and improve the performance of daily activities. The therapeutic mechanism is associated with the promotion of neuroplasticity and the elevation of Brain-Derived Neurotrophic Factor (BDNF) levels. In clinical research, it is frequently administered in conjunction with acupuncture at the Baihui (GV20) and Xuanzhong (GB39) points to synergistically enhance neurological outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fujianfang yisui formula.